Advertisement Sanofi, SK Chemical to develop new pneumococcal conjugate vaccine - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Sanofi, SK Chemical to develop new pneumococcal conjugate vaccine

Sanofi's vaccines division Sanofi Pasteur and South Korea-based SK Chemicals have entered into a long-term strategic cooperation to jointly develop a new pneumococcal conjugate vaccine (PCV).

The deal will allow Sanofi Pasteur to access the global PCV market of $4bn and the use of PCVs in all countries is recommended by the World Health Organization (WHO).

Under the deal, Sanofi will make an up-front payment of $23m to SK Chemicals.

The deal includes research & development (R&D), production and commercialization of a preventative pneumococcal disease vaccine.

As part of the deal, the two firms will co-invest in the development of the PCV vaccine project and, if successful, SK Chemicals will produce the new vaccine at its production facility located in An-dong, South Korea.

Following registration, the new product will be launched globally by Sanofi Pasteur with shared profits outside of South Korea, where SK would commercialise it with exclusive rights.

Sanofi Pasteur CEO Olivier Charmeil said the company is committed to driving the open innovation strategy in improving global public-health concerns, and to this end, this collaboration with SK Chemicals will showcase a win-win partnership built on mutual strengths and expertise of each company.

"With this agreement, Sanofi Pasteur will enlarge its unique portfolio of products, embracing the value of open innovation," Charmeil said.

SK Chemicals CEO In-Serk Lee said, "We are proud to partner with Sanofi Pasteur, one of the global leaders of the vaccine industry, to be able to develop and manufacture in Korea a premium vaccine that has the potential to be distributed worldwide."